Since the first sequencing of the human genome in 2003, tremendous gains have been made in understanding hereditary cancer syndromes, with over 50 having been identified. Non-invasive tests to assess a person’s inherited risk of developing certain cancers are abundant. However, the clinical utility of these tests is limited. Orbit Genomics’  OrbiSeq technology platform is based on novel DNA markers called microsatellites. Microsatellites are much more responsive than other genomic markers, providing personalized disease risk. They are your DNA’s early warning system.